Bristol Myers Squibb, Eli Lilly and Novo are among the limited partners in the pharmaceutical-focused venture firm's BGV IV fund, which has reached its final close.

UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.

Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.

Novo helped the cardiac pump developer CorWave secure series C funding to increase its total funding to over $95m.

The newly launched cancer therapy startup plans to initiate clinical trials this year after securing funding from Alexandria Real Estate Equities’ venture arm.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.

Biopolymer material decontamination company Karamedica and genomic sequencing provider Murrieta Genomics have both joined UC Riverside's newly-launched Life Sciences Incubator.

Partners Healthcare-backed precision oncology drug developer Scorpion has now raised a total of $270m in funding in the past year.